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Abstract
Influenza is an infectious disease and can lead to life-threatening complications like pneumonia. The
disease is caused by three types of RNA viruses called influenza types A, B and C, each consisting
of eight negative single-stranded RNA-segments encoding 11 proteins. Current annual vaccines
contain two type A strains and one type B strain and are capable of inducing strong antibody
responses to both the surface glycoprotein hemagglutinin and the neuraminidase. While these
vaccines are protective against vaccine viruses they are not effective against newly emerging viruses
that contain antigenic variations known as antigenic drift and shift. In nature, environmental
selection pressure generally plays a key role in selecting antigenic changes in the antigen
determining spots of hemagglutinin, resulting in changes in the antigenicity of the virus. Recently, a
new technology has been developed where influenza-specific IgG+ antibody-secreting plasma cells
can be isolated and cloned directly from vaccinated humans and high affinity monoclonal antibodies
can be produced within several weeks after vaccination. The new technology holds great promise
for the development of effective passive antibody therapy to limit the spread of influenza viruses in
a timely manner.
Background
Influenza is an infectious disease with symptoms of the
common cold such as chills, high fever, sore throat, mus-
cle pains, severe headache, coughing, bleeding from nose,
weakness and general discomfort, but it is a much more
severe disease as it can lead to life-threatening complica-
tions (like pneumonia) and death. Influenza is caused by
three types of RNA viruses called influenza types A, B and
C, which all belong to the orthomyxoviridae family. The
so called "flu" in humans is generally caused by the
viruses A and B, which are transmitted by aerosols from
infected individuals or through contact with infected ani-
mals [1]. The disease mainly attacks weaker populations
like children, old people and immune incompetent
patients. Historically, flu epidemics are responsible for the
deaths of millions of people. At present there is fear of
pandemics of aggressive avian H5N1, which has already
caused 382 cases of infection and 241 deaths according to
WHO statistics [2-4]. Structurally, each influenza virus
consists of eight negative single-stranded RNA-segments
encoding 11 proteins [2]. The current vaccine regime
against influenza is protective, which usually includes 2
strains of type A and 1 strain of type B capable of produc-
ing strong antibody responses to the surface glycoprotein
hemagglutinin (HA) and neuraminidase (NA) of these
viruses. However, like other RNA viruses, the HA and NA
antigens are highly variable, and this makes it difficult to
control new epidemics of influenza. Recent years have
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seen significant progress in this field, as exemplified by
the following two recent studies. The first study details the
relationship between changing environmental selective
pressure and antigenic changes in human influenza [5],
and the second one reports the identification of time-
dependent antibody response to an influenza vaccine
virus and rapid production of high affinity, virus-specific
human monoclonal antibodies [6]. These progresses will
prove to be essential for the development of effective
medical countermeasures to cope with influenza infection
and epidemics.
Antigen evolution pattern
Influenza antigenic properties are determined by both HA
and NA [7]. HA acts to attach the virus into host cells and
subsequently fuse it to cell membranes, which is essential
for the virus life cycle [8]. HA is synthesised as a single
peptide but cleaved into HA1 and HA2 by specific host
protease. The amino acids at the cleavage site are impor-
tant in determining the virulence of the virus, that is the
virus becomes highly virulent if these amino acids are
lipophilic, [8]. Immunity induced by HA has been shown
to increase host resistance to influenza and reduce the
likelihood of infection and severity [9]. However, such
protection is not effective against newly emerging influ-
enza viruses that contain antigenic variations known as
antigenic drift and shift [10]. Antigenic drift refers to a
minor change (such as amino acid substitution in HA
and/or NA) resulting in antigenic site change. In contrast,
antigenic shift is the formation of a new virus subtype
with mixed HA and NA from different subtypes. How do
these alterations occur? It has been shown that selection
pressure in the environment plays a key role in selecting
antigenic changes in the antigen determining spots of HA,
such as in places undergoing adaptive evolution and in
antigenic locations undergoing substitutions, resulting in
changes in the antigenicity of the virus [5]. It is also
known that glycosylation of HA does not correlate with
either the antigenicity or the selection pressure [5]. This
process represents the side of the pathogen to escape the
host defence through co-evolution with the host.
Antibody response to influenza infection
In the host, infection by an influenza virus triggers a series
of immune responses to counteract the invading virus.
Antibody response has been shown to play an important
role in protection against influenza virus infection [11].
Recently, Wrammert and colleagues demonstrated that
IgG+ antibody-secreting plasma cells (ASCs) increase rap-
idly to the highest level at day 7 after vaccination and then
return to minimal levels at day 14 while influenza-specific
memory B-cells peaks at day14–21 [6]. These ASCs are
newly divided rather than pre-existing as demonstrated by
the expression of the human leukocyte antigen and the
proliferation of antibody marker Ki-67 [6]. They also
demonstrated that the original antigen sin (OAS), which
refers to higher affinity for a previously encountered virus
than for the virus strain present in the vaccine, is unlikely
in the normal and healthy adults [6]. Most of the secreted
antibodies are specific to the vaccine virus. Among 86
monoclonal antibodies isolated, 61 have high binding
affinity for the vaccine virus [6], the majority (60%) of
which are against HA with the rest against NA, nucleopro-
tein (NP) and other antigens. The antibodies are also
shown to be able to neutralize viral infection in MDCK
cells, and therefore, they could play a crucial role in limit-
ing the spread of the virus [6].
Rapid antibody production and therapeutic 
implications
The current drug therapy for influenza infection is not sat-
isfactory. At present, only two classes of drugs have been
licensed for human use: M2 ion channel inhibitors
(amantadine, rimantadine) and neuraminidase inhibitors
(oseltamivir, zanamivir, peramivir). However, clinically
oseltamivir phosphate does not bring survival rate up [12-
14]. Strains that are resistant to amantadine have also
emerged which may compromise the current drug therapy
[15,16]. Undoubtly, the recent finding by Wrammert et al
[6] holds great promise for the development of passive
antibody therapy against the spread of influenza viruses
because (1) high affinity human monoclonal antibodies
can be produced in less than a month after vaccination
and (2) these antibodies, because of their human origin,
will have no or minimal antibody-related side-effects in
humans.
Role of intact host immune responses
Host responses against influenza include an intact and
functional cascade of changes including both innate and
adaptive immunities such as cytokine and interferon pro-
duction, macrophage function, dendritic cells, natural
killer cell function; and cytotoxic T lymphocyte activity,
influenza-specific antibodies. In mice, defects in inter-
feron α and β, complement system have been shown to
increase morbidity and mortality [17,18]. Natural killer
cells and macrophages are very early responses which are
critical for the host to counteract the infection [19]. CD8+
T cells clear influenza virus by perforin-mediated path-
ways [20,21]. Mice deficient in CD8+ T-cells have
increased viral replication and morbidity after infected
with PR8 [22]. CD4+ T-cells are essential for effective B-
cell responses to produce antibodies [21]. Plasmacytoid
dendritic cells (pDCs) can internalise viral antigens and
present them on major histocompatibility complex
(MHC) class I to CD8+ T-cells to enhance host immune
responses [23]. These defence mechanisms when work
together are very effective against virus infection. How-
ever, there are also cases where the stimulation of only
some of the elements in the immune system may bePublish with BioMed Central    and   every 
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required to synergize the use of anti-influenza antibodies.
Potentially, anti-M2 antibody may also be used against
influenza infection as M2 is not variable compared to HA
and NA [24].
In summary, the clinical outcome of influenza depends
on both the influenza virus and the host defence. Recent
studies have furthered our understanding about virus
antigenic variation to escape the host immune system.
Recent advances, particularly, in rapid production of
human antibodies to influenza viruses will help develop
new medical countermeasures to control influenza epi-
demics.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JC and YD jointly wrote the manuscript, read and
approved it.
Acknowledgements
The WHO Collaborating Centre for Reference and Research on Influenza 
is supported by the Australian Government Department of Health and 
Ageing.
References
1. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen
DH, de Jong MD, Naghdaliyev A, Peiris JS, Shindo N, Soeroso S, Uyeki
TM: Update on avian influenza A (H5N1) virus infection in
humans.  The New England journal of medicine 2008, 358(3):261-273.
2. Ghedin E, Sengamalay NA, Shumway M, Zaborsky J, Feldblyum T,
Subbu V, Spiro DJ, Sitz J, Koo H, Bolotov P, Dernovoy D, Tatusova T,
Bao Y, St George K, Taylor J, Lipman DJ, Fraser CM, Taubenberger
JK, Salzberg SL: Large-scale sequencing of human influenza
reveals the dynamic nature of viral genome evolution.  Nature
2005, 437(7062):1162-1166.
3. Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka
Y: Human infection with highly pathogenic H5N1 influenza
virus.  Lancet 2008, 371(9622):1464-1475.
4. WHO: 2008 [http://www.who.int/csr/disease/avian_influenza/en/].
5. Blackburne BP, Hay AJ, Goldstein RA: Changing selective pres-
sure during antigenic changes in human influenza H3.  PLoS
pathogens 2008, 4(5):e1000058.
6. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C,
Zheng NY, Mays I, Garman L, Helms C, James J, Air GM, Capra JD,
Ahmed R, Wilson PC: Rapid cloning of high-affinity human
monoclonal antibodies against influenza virus.  Nature 2008.
7. Oxford JS: Influenza A pandemics of the 20th century with
special reference to 1918: virology, pathology and epidemi-
ology.  Reviews in medical virology 2000, 10(2):119-133.
8. Skehel JJ, Wiley DC: Receptor binding and membrane fusion in
virus entry: the influenza hemagglutinin.  Annual review of bio-
chemistry 2000, 69:531-569.
9. Clements ML, Betts RF, Tierney EL, Murphy BR: Serum and nasal
wash antibodies associated with resistance to experimental
challenge with influenza A wild-type virus.  Journal of clinical
microbiology 1986, 24(1):157-160.
10. Ping J, Li C, Deng G, Jiang Y, Tian G, Zhang S, Bu Z, Chen H: Single-
amino-acid mutation in the HA alters the recognition of
H9N2 influenza virus by a monoclonal antibody.  Biochemical
and biophysical research communications 2008, 371(1):168-171.
11. Gerhard W: The role of the antibody response in influenza
virus infection.   Curr Top Microbiol Immunol 2001, 260:171-190.
12. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC,
Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH, Farrar J:
Oseltamivir resistance during treatment of influenza A
(H5N1) infection.  The New England journal of medicine 2005,
353(25):2667-2672.
13. Moscona A: Oseltamivir resistance–disabling our influenza
defenses.  The New England journal of medicine 2005,
353(25):2633-2636.
14. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham
ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada a,
Goto H, Suzuki T, Suzuki Y, Kawaoka Y: Avian flu: isolation of
drug-resistant H5N1 virus.  Nature 2005, 437(7062):1108.
15. Li KS, Guan Y, Wang J, Smith GJ, Xu KM, Duan L, Rahardjo AP, Putha-
vathana P, Buranathai C, Nguyen TD, Estoepangestie AT, Chaisingh A,
Auewarakul P, Long HT, Hanh NT, Webby RJ, Poon LL, Chen H,
Shortridge KF, Yuen KY, Webster RG, Peiris JS: Genesis of a highly
pathogenic and potentially pandemic H5N1 influenza virus
in eastern Asia.  Nature 2004, 430(6996):209-213.
16. Barr IG, Deng YM, Iannello P, Hurt AC, Komadina N: Adamantane
resistance in influenza A(H1) viruses increased in 2007 in
South East Asia but decreased in Australia and some other
countries.  Antiviral Research 2008 in press.
17. Haller O, Arnheiter H, Gresser I, Lindenmann J: Genetically deter-
mined, interferon-dependent resistance to influenza virus in
mice.  The Journal of experimental medicine 1979, 149(3):601-612.
18. Kopf M, Abel B, Gallimore A, Carroll M, Bachmann MF: Comple-
ment component C3 promotes T-cell priming and lung
migration to control acute influenza virus infection.  Nature
medicine 2002, 8(4):373-378.
19. Tsuru S, Fujisawa H, Taniguchi M, Zinnaka Y, Nomoto K: Mecha-
nism of protection during the early phase of a generalized
viral infection. II. Contribution of polymorphonuclear leuko-
cytes to protection against intravenous infection with influ-
enza virus.  The Journal of general virology 1987, 68(Pt 2):419-424.
20. Topham DJ, Tripp RA, Doherty PC: CD8+ T cells clear influenza
virus by perforin or Fas-dependent processes.  J Immunol 1997,
159(11):5197-5200.
21. Doherty PC, Topham DJ, Tripp RA, Cardin RD, Brooks JW, Steven-
son PG: Effector CD4+ and CD8+ T-cell mechanisms in the
control of respiratory virus infections.  Immunological reviews
1997, 159:105-117.
22. Bender BS, Croghan T, Zhang L, Small PA Jr: Transgenic mice lack-
ing class I major histocompatibility complex-restricted T
cells have delayed viral clearance and increased mortality
after influenza virus challenge.  The Journal of experimental medi-
cine 1992, 175(4):1143-1145.
23. Di Pucchio T, Chatterjee B, Smed-Sorensen A, Clayton S, Palazzo A,
Montes M, Xue Y, Mellman I, Banchereau J, Connolly JE: Direct pro-
teasome-independent cross-presentation of viral antigen by
plasmacytoid dendritic cells on major histocompatibility
complex class I.  Nature immunology 2008, 9(5):551-557.
24. Mozdzanowska K, Zharikova D, Cudic M, Otvos L, Gerhard W:
Roles of adjuvant and route of vaccination in antibody
response and protection engendered by a synthetic matrix
protein 2-based influenza A virus vaccine in the mouse.  Virol-
ogy journal 2007, 4:118.